Telix QSAM Inc (QSAM)

[Timing101]

I find this company interesting, but what is it as of today really.
--
The QPWR side of the Organics.. makes sense with the Mgt Team
http://q2earth.com/
--
One could see the connections and experience, besides being current and QB stock..
--
The 10K does mention a R/S but very small back in March 2020 and they
have not applied it after all this time .
Quote
"The proposal to amend the Company’s Charter to effect a reverse stock split of the outstanding shares of the Company’s Common Stock by a ratio of not less than 1:2 shares and not more than 1:25 shares, with the exact ratio to be set at a whole number within this range by the Board of Directors of the Company in its sole discretion, was approved with a vote of 32,034,165 shares FOR and 3,072,686 shares AGAINST the proposal.


? The proposal to adopt the Amended Omnibus Equity Incentive Plan was approved with a vote of 25,594,768 shares FOR and 2,333,068 shares AGAINST the proposal, with 455,735 shares abstaining from the vote.


As of April 14, 2020, the Company has not yet filed amendments to its Charter to increase the number of authorized Common Stock or to institute a reverse split." end quote

==================

Earlier in the year they appointed a new Director and then the Bio Science came out , yet TBD there
--
Their spin on it was on the appointment and the statement of HEALTH
**
"Mr. Baum brings to the Company over 28 years of experience in the bioscience and biotech industries, including development, commercialization and marketing of multiple drugs and medical devices. Over his long senior executive tenure, including as CEO of Xeris Pharmaceuticals, he has overseen 15 product approvals through the FDA and raised over $80 million in capital to fund breakthrough technologies.

“We are pleased and honored to have Doug join our board. We have a great deal of faith that he can help us pursue a strategy that includes expanding our licensing portfolio and business lines into new areas of biotechnology.” stated Kevin Bolin, the Company’s Chairman and CEO.

Mr. Baum stated: “This is an exciting opportunity for me, and I look forward to working with the Q2 team. I feel confident that I can help the Company execute its vision and bring interesting opportunities to the table in the short term while building long-term shareholder value.”

The Board of Directors of Q2 has authorized a strategic plan for 2020 which is comprised of: (1) securing new technologies and business opportunities in the broader biosciences sector, including both human and soil health; and (2) significantly reducing debt and liabilities of the Company and eliminating under-performing assets and agreements. The successful results of these actions are intended to attract new capital to fund long term growth opportunities for the Company."